Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...

Scientists 'reprogram' tumour-supporting immune cells

The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...

Existing medicines could help treat deadly childhood dementia

Australian researchers have identified several existing TGA‑approved medicines that could help...

Content from other channels on our network

Keeping the healthcare sector clean

How effective are ML algorithms in ICU mortality predictions?

Doctors' inaugural Aged Care Report Card reveals "failures" across the sector

Top 5 insights into why older Australians stop eating well at home

Trusted Knowledge for Clinical Practice and Education: Supporting Australia's Health Workforce Through Change

Small changes for manufacturing healthier food

Fat recovery method for industrial ice-cream waste

SMaRT-Pack centre to help drive sustainable packaging transition

Air Liquide to build industrial and medical gas plant in NSW

How AI is changing the way food and beverage manufacturers prevent and manage recalls

4 common causes of rotating asset failure and how to prevent them

Peacock Bros. and insignia to unite under one roof in Victoria

First prospective tenants identified for Western Defence Forge

80% of ANZ operational systems hit with a cyber attack in the past year

Automated cell therapy manufacturing system wins Good Design Award